PGAM5 Antibody (C-1): sc-515881

PGAM5 Antibody (C-1) is a mouse monoclonal IgG2a antibody that detects PGAM5 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). PGAM5, also known as Bcl-xL-binding protein v68, is a 289 amino acid protein that plays a crucial role in cellular metabolism, particularly in the conversion of phosphoglycerates, which is essential for energy production and metabolic regulation. PGAM5 belongs to the BPG-dependent phosphoglycerate mutase subfamily and exists in two isoforms due to alternative splicing; isoform one is found in both the cytoplasm and nucleus, while isoform two is localized solely in the cytoplasm. The dimeric structure of PGAM5 allows interaction with key proteins such as Bcl-xS/L and Keap1, which are involved in apoptosis and oxidative stress responses, respectively. Understanding the interactions and functions of PGAM5 is vital for elucidating its role in metabolic pathways and potential implications in diseases related to energy metabolism and cell survival. Anti-PGAM5 antibody (C-1) is an invaluable tool for researchers investigating these critical biological processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PGAM5 Antibody (C-1) References:

1. Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway.  |  Liu, X., et al. 2020. Metabolism. 111: 154334. PMID: 32777444
2. IFN-β rescues neurodegeneration by regulating mitochondrial fission via STAT5, PGAM5, and Drp1.  |  Tresse, E., et al. 2021. EMBO J. 40: e106868. PMID: 33913175
3. A novel PGAM5 inhibitor LFHP-1c protects blood-brain barrier integrity in ischemic stroke.  |  Gao, C., et al. 2021. Acta Pharm Sin B. 11: 1867-1884. PMID: 34386325
4. PGAM5 expression levels in heart failure and protection ROS-induced oxidative stress and ferroptosis by Keap1/Nrf2.  |  Li, S., et al. 2023. Clin Exp Hypertens. 45: 2162537. PMID: 36780919
5. PGAM5 exacerbates acute renal injury by initiating mitochondria-dependent apoptosis by facilitating mitochondrial cytochrome c release.  |  Li, JY., et al. 2024. Acta Pharmacol Sin. 45: 125-136. PMID: 37684381
6. Mitochondrial PGAM5-Drp1 signaling regulates the metabolic reprogramming of macrophages and regulates the induction of inflammatory responses.  |  Bang, BR., et al. 2023. Front Immunol. 14: 1243548. PMID: 37771598
7. Deletion of PGAM5 Downregulates FABP1 and Attenuates Long-Chain Fatty Acid Uptake in Hepatocellular Carcinoma.  |  Muthusamy, G., et al. 2023. Cancers (Basel). 15: PMID: 37835490
8. PGAM5 degrades PDCoV N protein and activates type I interferon to antagonize viral replication.  |  Yang, X., et al. 2023. J Virol. 97: e0147023. PMID: 37882521
9. Pgam5 aggravates hyperglycemia-induced myocardial dysfunction through disrupting Phb2-dependent mitochondrial dynamics.  |  Chen, Y., et al. 2024. Int J Med Sci. 21: 1194-1203. PMID: 38818468
10. PGAM5 interacts with and maintains BNIP3 to license cancer-associated muscle wasting.  |  Zhang, Q., et al. 2024. Autophagy. 20: 2205-2220. PMID: 38919131

The preferred PGAM5 antibody is PGAM5 Antibody (A-3): sc-515880.